The global Hemophilia A treatment market was valued at approximately USD 8 billion in 2016. The Report covers the Hemophilia A therapeutic area, prevalent population, current treatment and diagnosis patterns. The Report provides the forecast of Hemophilia A treatment market globally, by G7 countries, disease care at product level. The Report also offers an in-depth view of the Hemophilia A treatment market opportunities by focusing on major drivers facing this market. Hemophilia A, also called factor VIII (FVIII) deficiency or classic Hemophilia, is a genetic disorder caused by missing or defective factor VIII, a clotting protein. Although it is passed down from parents to children, about 1/3 of cases are caused by a spontaneous mutation, a change in a gene.
Hemophilia A market accounts for the largest share in total Hemophilia treatment market due to the rising prevalence and increase in demand of prophylactic treatments. In terms of the geographic distribution, Unites States holds the dominant market position followed by top five European countries (France, Germany, Italy, Spain and the U.K.) and Japan. The major drivers of the U.S. market are rising prevalent cases of Hemophilia A, awareness of the disease, access to new treatment modalities, improved diagnosis, and increase in the usage of both prophylactic and recombinant treatment options.
The market for Haemophilia A treatment market looks commercially significant driven by increase rising demand for recombinant and prophylaxis products and continual increase in new cases diagnosed each year worldwide. Despite the existence of available effective treatment options in Hemophilia A, there is currently no cure for Hemophilia A. Also, these therapies are expensive and involve lifelong therapy to prevent bleeding.
Polaris Market Research has provided the forecasts of the Global Hemophilia A treatment Market from 2016-2022. The major segments which has been investigated in the global market from 2016-2022 are: